This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
General Information
Mouse: CB57BL/6J
Expression of the human C-terminal-truncated (1-130) mutant A53T alpha-synuclein under the control of the rat tyrosine hydroxylase (TH) promoter.
Endogenous mouse alpha synuclein: Yes
Corresponding human genotype: The A53T mutation causes an autonomous dominant form of the disease. Truncated alpha-synuclein is enriched in human Lewy body extracts
Transgene insertion: not specified
References: Wakamatsu 2008a; Wakamatsu 2008b
Transgene expression
- 6 weeks – 52 weeks: transgene expression is observed in the midbrain at reduced levels (30-60%) compared to those of endogenous alpha-synuclein. Alpha-synuclein protein is observed in the soma and nuclei of neurons.
Neurodegeneration
- 8, 26 and 52 weeks: significant loss (20-45%) of TH-positive neurons is observed in the SN. This loss is observed at 8 weeks and remains stable for up to 52 weeks. A 50% reduction of TH is observed in the striatum at 8 and 52 weeks of age.
Dopamine Homeostasis
- 8 and 52 weeks: Both dopamine and homovanillic acid levels are significantly reduced in the striatum
Inclusions
- Not reported
Motor Behaviours
- 8 and 52 weeks: reduction in spontaneous locomotor activity.
- 8 and 52 weeks: no deficits are observed in the rotarod, pole, traction or catalepsy tests.
Response to L-DOPA treatment
- 8 and 52 weeks: Treatment with L-DOPA or dopamine receptor agonists (quinpirole, talipexole, pergolide) induce recovery of spontaneous locomotor activity
Non motor Behaviours
- Not reported
Electrophysiology
- Not reported
Neuroinflammation
- Not reported